Galectin-3 and Placenta Accreta

The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04573452

Enrollment

Registered

2020-10-05

Start date

2020-10-01

Completion date

2021-10-01

Last updated

2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Brief summary

Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell. They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues. Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis. Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.

Interventions

DIAGNOSTIC_TESTGalectin-3

Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).

DIAGNOSTIC_TESTPlacental Galactin-3

Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

1. Pregnant women between 28-32 weeks. 2. Age between 20-40 years. 3. Singleton pregnancy. 4. Women with suspicion of placenta accreta 5. Cases with mild vaginal bleeding or not having any vaginal bleeding.

Exclusion criteria

1. Women are known to have any medical disorders. 2. Patients with known bleeding disorders or on anticoagulant therapy. 3. Patients refuse to participate.

Design outcomes

Primary

Measure	Time frame	Description
Galactin 3 level in the blood	6 weeks	measured by ng/ml

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026